Liraglutide Medicare Part D Coverage: What You Actually Pay in 2026

How Medicare Part D Handles Liraglutide in 2026

Medicare Part D plans are required to cover FDA-approved medications for their approved indications, and liraglutide injection (brand name Victoza) holds FDA approval for glycemic control in adults with type 2 diabetes. That means most Part D formularies list it. The catch is tier placement: your plan decides whether liraglutide lands on a preferred brand tier with a $35 to $47 co-pay or a non-preferred tier with 25% to 33% coinsurance.

The Inflation Reduction Act (IRA) reshaped Part D economics starting in 2025 by capping total beneficiary out-of-pocket spending at $2,000 per year. Before the IRA, a Part D enrollee using brand Victoza could pay $3,000 or more annually once they entered the coverage gap. That gap no longer exists in its old form. Once your accumulated true out-of-pocket costs hit $2,000, your plan covers 100% of remaining drug costs for the rest of the calendar year.

This matters for liraglutide specifically because it is a continuously used injectable. A patient filling 12 months of Victoza at a Tier 4 coinsurance rate of 25% on a $1,000 list price would previously have owed roughly $3,000 in the coverage gap alone. Under the 2025/2026 structure, that same patient hits the $2,000 cap around month five or six and pays nothing for the remaining fills.

Beneficiaries eligible for the Low-Income Subsidy (Extra Help or LIS) pay even less. Full-subsidy LIS enrollees owe $0 for generic drugs and $4.50 for brands in 2026. Partial-subsidy enrollees face a 15% coinsurance up to the annual cap.

Why Saxenda Is Not Covered (and What to Do About It)

Liraglutide at the 3 mg daily dose is sold as Saxenda for chronic weight management. Medicare Part D has a statutory exclusion for drugs used for "anorexia, weight loss, or weight gain" under Section 1860D-2(e)(2)(A) of the Social Security Act. This exclusion blocks coverage regardless of the patient's BMI, comorbidities, or prescriber rationale.

The Treat and Reduce Obesity Act (TROA) has been reintroduced in multiple congressional sessions to remove this exclusion. As of May 2026, it has not passed. Until it does, Medicare beneficiaries who want liraglutide specifically for weight loss must pay the full cash price or explore alternatives.

Options that some patients use include requesting liraglutide under the diabetes indication (if they have a qualifying A1c), switching to tirzepatide (Zepbound has the same statutory barrier for obesity, but Mounjaro is covered for diabetes), or using compounded liraglutide purchased outside their Part D plan. The American Association of Clinical Endocrinology (AACE) 2023 obesity treatment algorithm includes GLP-1 receptor agonists as first-line pharmacotherapy for patients with BMI ≥30, reinforcing the clinical rationale even when payer policy lags behind the evidence.

Generic Liraglutide: What's Available and What It Costs

The FDA approved the first generic liraglutide injection in late 2024. Generic entry changed the pricing picture, though not as dramatically as oral generics typically do. Injectable biologics and their follow-on products (technically liraglutide generics under the 505(b)(2) pathway) tend to discount at 20% to 40% off brand, not the 80% to 90% seen with small-molecule generics.

Cash-pay prices for generic liraglutide pens currently sit between $400 and $600 per month at major retail pharmacies, compared to roughly $900 to $1,100 for brand Victoza. With a GoodRx or RxSaver coupon, some patients report prices below $400 at Costco and select independent pharmacies.

For Medicare Part D enrollees, the generic's lower list price translates directly into lower coinsurance amounts in the initial coverage and catastrophic phases. A plan charging 25% coinsurance on a $500 generic versus a $1,000 brand means the difference between reaching the $2,000 cap in month four versus month eight. This arithmetic matters. Every additional month before hitting the cap is another $125 out of pocket.

Plans that already list brand Victoza typically auto-substitute to a generic when available, but formulary rules vary. Some plans require the prescriber to specify "dispense as written" to get the brand; others may not have added the generic to their formulary yet in the mid-year cycle. Always verify your specific plan's formulary at Medicare Plan Finder.

Compounded Liraglutide: The $150 Alternative

Compounding pharmacies registered under FDA Section 503B can produce liraglutide injection when they meet certain conditions, including using bulk drug substance that meets USP standards. Compounded liraglutide is not FDA-approved as a finished product, but it is legal to dispense with a valid prescription.

Prices for compounded liraglutide typically run $100 to $200 per month, a fraction of brand or generic costs. The trade-off is that compounded products do not go through the same batch-level FDA review as commercially manufactured drugs, potency can vary between compounding pharmacies, and Medicare Part D will not reimburse for compounded injectables in most cases.

Dr. Caroline Apovian, in a 2015 Obesity review on long-term pharmacotherapy for obesity, noted that "cost remains the primary barrier to sustained GLP-1 receptor agonist use" and that "access strategies must evolve alongside the clinical evidence." This observation remains accurate a decade later. Patients who cannot afford branded or generic liraglutide through their Part D plan sometimes pay cash for compounded versions, using their Part D benefit for other medications where the coverage provides more value.

The FDA's guidance on compounding clarifies that 503B outsourcing facilities must register with the FDA and comply with current good manufacturing practices. Patients should verify that any compounding pharmacy they use holds 503B registration and can provide a certificate of analysis for potency and sterility.

Step Therapy, Prior Authorization, and Quantity Limits

Most Part D plans impose at least one utilization management tool on liraglutide. The three most common are prior authorization (PA), step therapy (ST), and quantity limits (QL).

Prior authorization for liraglutide typically requires documentation of a type 2 diabetes diagnosis with A1c above 7.0%, a trial of metformin (unless contraindicated), and sometimes a trial of a sulfonylurea or SGLT2 inhibitor. The American Diabetes Association (ADA) 2024 Standards of Care position GLP-1 receptor agonists as preferred second-line therapy after metformin for patients with established atherosclerotic cardiovascular disease or high cardiovascular risk, which can expedite PA approval.

Step therapy requirements vary by plan. Some require failure of at least one oral GLP-1 (oral semaglutide/Rybelsus) before approving injectable liraglutide. Others require a trial of a cheaper injectable like insulin glargine. The LEADER trial (N=9,340) demonstrated that liraglutide reduced major adverse cardiovascular events by 13% versus placebo in patients with type 2 diabetes and high cardiovascular risk (HR 0.87, 95% CI 0.78 to 0.97, P=0.01). Citing this data in an appeal letter can help overturn a step therapy denial when cardiovascular benefit is the clinical rationale.

Quantity limits for liraglutide usually cap dispensing at one 3-pen carton (18 mg total) per 30 days for the 1.8 mg daily diabetes dose. Patients titrating from 0.6 mg may encounter early fills that appear to exceed QL because the titration schedule uses less drug per day, leaving unused medication.

How to Appeal a Part D Denial

If your Part D plan denies liraglutide coverage, you have a structured five-level appeals process under 42 CFR § 423.562. The first level is a plan-level redetermination. Your prescriber submits a letter of medical necessity explaining why liraglutide is required and alternatives are inadequate. Plans must decide within 7 calendar days (72 hours for expedited requests).

Data strengthens appeals. If you have documented intolerance to metformin (GI side effects in up to 25% of patients per a 2017 Diabetes Care analysis), include that. If you have cardiovascular disease and the LEADER trial data applies, reference it explicitly. If prior GLP-1 agents caused adverse effects, document the dates and outcomes.

The second level goes to an Independent Review Entity (IRE). The third through fifth levels escalate through an Administrative Law Judge, Medicare Appeals Council, and federal district court. Fewer than 5% of Part D appeals reach level three. Most succeed or fail at levels one and two.

Comparing Liraglutide Costs Across Coverage Scenarios

Understanding where you fall in the Part D benefit structure determines your real cost. Here is a representative example for a beneficiary using generic liraglutide (estimated plan cost: $500/month) on a standard 2026 Part D plan with 25% coinsurance:

The deductible phase runs from $0 to $590 in total drug costs. You pay 100% during this phase, so the first month costs $500 out of your own pocket (if you haven't used other drugs). Once you pass the deductible, you enter the initial coverage phase, paying 25% coinsurance: $125 per month. After your true out-of-pocket reaches $2,000 (approximately month four or five, depending on deductible math), you enter the catastrophic phase and owe $0 for the rest of the year.

For brand Victoza at $1,000/month with the same plan design: the deductible consumes month one at $590 out-of-pocket, then months two and three charge $250 each (25% of $1,000). You hit the $2,000 cap partway through month four. Total annual cost: $2,000 either way if you use the drug all year, but the generic gets you to $0 monthly payments faster.

A beneficiary on a plan with a $0 deductible for preferred generics (some Medicare Advantage Part D plans offer this) skips straight to the coinsurance phase, potentially saving $500 in month one.

Patient Assistance Programs and Other Cost-Cutting Strategies

Novo Nordisk's patient assistance program (PAP) provides free Victoza to qualifying patients whose household income falls below 400% of the federal poverty level. Medicare beneficiaries are eligible for the PAP but are not eligible for manufacturer co-pay cards due to Anti-Kickback Statute restrictions. This is a common point of confusion. The savings card advertised on Victoza's website explicitly excludes government insurance.

For patients not on Medicare, the Victoza Savings Card can reduce co-pays to as low as $25 for up to 24 months. The generic liraglutide manufacturers may offer their own savings programs; check each manufacturer's website directly, as programs launch and expire without central tracking.

The SCALE Obesity and Prediabetes trial (N=3,731) showed that liraglutide 3.0 mg produced 8.0% mean body weight loss versus 2.6% with placebo at 56 weeks. For patients whose primary goal is weight loss but who also carry a diabetes diagnosis, prescribing under the diabetes indication (at 1.8 mg daily) provides Part D-covered access to the same molecule, though the dose is lower than the obesity-approved 3.0 mg.

State Pharmaceutical Assistance Programs (SPAPs) exist in roughly 20 states and can wrap around Part D to cover co-pays or provide additional subsidies. The Medicare.gov SPAP directory lists active programs by state. Some SPAPs specifically include GLP-1 receptor agonists; others exclude injectables.

Liraglutide vs. Other GLP-1s on Medicare Part D

Liraglutide is not the only GLP-1 receptor agonist on Part D formularies, and plan economics sometimes favor a switch. Dulaglutide (Trulicity) is weekly instead of daily and often sits on a preferred brand tier with lower coinsurance. Semaglutide injection (Ozempic) provides greater A1c reduction (1.5% to 1.8% vs. 1.0% to 1.5% for liraglutide, per the SUSTAIN trial program) and weekly dosing, but its list price is higher.

The 2024 ADA Standards of Care do not rank GLP-1 receptor agonists against each other by preference. The choice often comes down to formulary tier, co-pay, and patient injection frequency preference. A beneficiary paying $250/month coinsurance for non-preferred Ozempic might pay $47 for preferred Trulicity on the same plan. Checking your plan's formulary before your prescriber writes the script can save hundreds of dollars per year within the same drug class.

For patients already stable on liraglutide with good glycemic control and tolerability, switching agents to save money introduces a risk of GI side effects during re-titration and a temporary period of glycemic instability. Dr. John Buse, in the ADA's 2024 consensus report, stated that "therapeutic inertia causes more harm than the cost of continuing an effective regimen" when discussing GLP-1 agonist switches driven by formulary changes.

What Changes to Watch in 2026 and 2027

Three developments could reshape liraglutide coverage for Medicare beneficiaries. First, CMS selected the first 10 drugs for Medicare price negotiation under the IRA in 2023, with prices taking effect in 2026. Liraglutide was not in this first cohort, but GLP-1 receptor agonists as a class are candidates for future rounds. If semaglutide (Ozempic/Wegovy) enters negotiation in a future cycle, the negotiated price could shift formulary preferences across all GLP-1s.

Second, generic competition may intensify. Additional generic liraglutide applicants are in the FDA pipeline, and each new entrant typically drives further price reduction.

Third, the TROA legislation or similar obesity-drug coverage bills remain active. If Medicare gains the authority to cover anti-obesity medications, Saxenda (liraglutide 3.0 mg) would become Part D-eligible, opening coverage for an estimated 9 million Medicare beneficiaries with obesity who currently have no Part D pathway to GLP-1 therapy for weight management.

Verify your plan's current formulary and cost-sharing at Medicare Plan Finder before each annual enrollment period, and request a coverage determination from your plan 72 hours before filling a new liraglutide prescription to confirm your expected co-pay.